{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:38:04Z","timestamp":1707525484763},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.7759\/cureus.49767","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T08:13:36Z","timestamp":1701418416000},"source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia Gravis Associated With Pembrolizumab for Relapsed Lung Cancer After Thymoma Resection"],"prefix":"10.7759","author":[{"given":"Shinya","family":"Otsuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2019.09.002","article-title":"Immune checkpoints in thymic epithelial tumors: challenges and opportunities","volume":"3","author":"Girard N","year":"2019","unstructured":"Girard N. Immune checkpoints in thymic epithelial tumors: challenges and opportunities. Immunooncol Technol. 2019, 3:8-14. 10.1016\/j.iotech.2019.09.002","journal-title":"Immunooncol Technol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard C","year":"2016","unstructured":"Bernard C, Frih H, Pasquet F, et al.. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev. 2016, 15:82-92. 10.1016\/j.autrev.2015.09.005","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.059","article-title":"Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study","volume":"174","author":"Wang W","year":"2022","unstructured":"Wang W, Lin G, Hao Y, et al.. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study. Eur J Cancer. 2022, 174:21-30. 10.1016\/j.ejca.2022.06.059","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki S","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al.. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-34. 10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000422","article-title":"Pembrolizumab-induced myasthenia gravis: literature review of ocular manifestations and a refractory case","volume":"45","author":"Dugena O","year":"2022","unstructured":"Dugena O, Zheng C, Taylor J, Wong A. Pembrolizumab-induced myasthenia gravis: literature review of ocular manifestations and a refractory case. J Immunother. 2022, 45:267-73. 10.1097\/CJI.0000000000000422","journal-title":"J Immunother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone G","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, et al.. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018, 19:347-55. 10.1016\/S1470-2045(18)30062-7","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho J","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, et al.. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019, 37:2162-70. 10.1200\/JCO.2017.77.3184","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti F","year":"2022","unstructured":"Conforti F, Zucali PA, Pala L, et al.. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022, 23:1287-96. 10.1016\/S1470-2045(22)00542-3","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205798-myasthenia-gravis-associated-with-pembrolizumab-for-relapsed-lung-cancer-after-thymoma-resection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:50Z","timestamp":1707509270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205798-myasthenia-gravis-associated-with-pembrolizumab-for-relapsed-lung-cancer-after-thymoma-resection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.49767","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}